Company​

Snapshot of the Company

Who We Are

Argent BioPharma (“RGT”) is emerging as an Innovative Drug Discovery clinical-stage Biopharmaceutical company, listed on the Australian Stock Exchange. Our commitment to providing accessible medical treatments for unmet medical needs is now being enhanced by the integration of Polypharmacology and Nanotechnology.

Early-Stage Revenues

Our Investigational Medicinal Products (IMP) are being prescribed through Early Patient access schemes in the UK, USA, Europe, and Australia.

Real-World
Data

Our treatments, provided to patients through an early access scheme, yield real-world data on safety and efficacy, complementing our clinical trials.

Research
Facility

Our European research hub is a powerhouse of innovation, where new ideas are nurtured into medical treatments. This facility supports our drug development lifecycle, from concept to commercial launch.

Clinical Trials

Our clinical trials are designed to ensure the safety and efficacy of our therapies, with real-world data from early access programs further supporting our research and development efforts.

Product Portfolio

Our focus in is on developing innovative treatments using NanoPolyPharmacology, particularly in immunology and neurology, with a strategic plan to introduce new treatments every four years. All our clinical trials are according to the US FDA Good Clinical Practice (GCP).

CimetrA®

Designed for the treatment of acute lung injury and acute respiratory distress syndrome (ARDS), currently in Phase 2B studies in Israel and already generates revenues through the early access schemes.

CannEpil® 

Designed as a seizure control treatment for patients with refractory epilepsy and cerebral palsy, entering Phase 2B under the FDA in 2025, generates revenues through the early access schemes.

CogniCann®

Designed to improve the quality of living in Dementia and Alzheimer patients, completed phase 2A studies in Australia.  

Our Strategic Direction

Purpose

Addressing unmet medical needs by integrating Polypharmacology and Nanotechnology.

Vision

To become a globally recognized Biopharmaceutical
company, providing accessible,
impactful solutions in healthcare.

Mission

To research and develop innovative
treatments, focusing on global health
challenges, with an emphasis
on immunology and neurology.

Key Strategy Pillars

Pioneering in Life Science

Improving healthcare with innovative Polypharmacology treatments.

Consistent Innovation

Regularly introducing new novel treatments based of Polypharmacology and Nanotechnology.

Global Accessibility

Ensuring our treatments are accessible worldwide.

Industry Leadership

Aiming to set new benchmarks in the Biopharmaceutical industry with multidiscipline innovative treatments.

01

Innovation at Argent BioPharma

Our R&D emphasises understanding disease mechanisms, developing innovative immunotherapies, and harnessing Polypharmacology and Nanotechnology.
We maintain a collaborative, open R&D culture, engaging in strategic partnerships and upholding the highest standards of ethical research.
02

Our Commitment to Values and Governance

We uphold Integrity, embrace Diversity, foster Teamwork, are Accountable, and strive for Excellence.
Our approach is underpinned by strong Environmental, Social, and Governance principles, focusing on diversity, equity, inclusion, environment, and product governance.